Phantom Pharmaceuticals Inc. has announced FDA approval for its Voquezna Triple and Dual Paks for the treatment of Helicobacter pylori infection in adults.According to a press release, the new drug applications for Voquenza Triple Pak (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets; Phantom Pharmaceuticals) and Voquenza Dual Pak (vonoprazan tablets, amoxicillin capsules; Phantom Pharmaceuticals) were given priority review designation by the FDA after previous classification as qualified infectious disease products. Both regimens contain vonoprazan, an innovativeRead More
- (305) 687-1367
- info@flgastro.org
- Mon - Fri: 9:00am - 5:00pm